

# Compounded GLP-1 Injection Order Form

Clinic Name: \_\_\_\_\_ Person Faxing: \_\_\_\_\_  
 Prescriber Name (please print): \_\_\_\_\_ NPI: \_\_\_\_\_  
 Office Phone: \_\_\_\_\_ Office Fax: \_\_\_\_\_  
 Address: \_\_\_\_\_ City, State, Zip: \_\_\_\_\_  
 Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

Patient Address: \_\_\_\_\_ City, State, Zip: \_\_\_\_\_

Patient Phone #: \_\_\_\_\_ Drug Allergies: \_\_\_\_\_

Email for Tracking Information (optional): \_\_\_\_\_

Select One: ☐ Ship/Deliver to Prescriber's Office Address ☐ Ship/Deliver to Patient's Home Address  
 Select One: ☐ Bill to Prescriber ☐ Bill to Patient

**REQUIRED: Selection reason for non-essential copy.** The dose and reason the FDA approved version is not appropriate for this patient will be screened by a pharmacist to ensure compliance with FDA regulations.

I, as the healthcare provider, attest to the following:

- ☐ My patient has an allergy to an ingredient in the commercial product  
☐ My patient requires microdosing or altered titration due to medical need, clinic protocol, or to decrease side effects  
☐ My patient receives a clinical difference with less side effects (nausea/vomiting) with leucine & pyridoxine at the time of admin  
☐ My patient receives a clinical difference from vitamin B supplementation due to delayed gastric emptying, the potential impact of nutrient absorption, and/or the affect of vitamin B's role in energy metabolism, fatigue, weakness, and neuropathy  
☐ Other: \_\_\_\_\_

**Rx COMPOUNDED INJECTIONS:** (CDC & FDA recommend to discard multi-use vials 28 days after first puncture)

☐ **Semaglutide / Leucine / Pyridoxine 5 / 10 / 10 mg / mL**

- |                                                  |                                                                         |                |
|--------------------------------------------------|-------------------------------------------------------------------------|----------------|
| <input type="checkbox"/> DISP: 1 mL vial         | Inject 8 units ( <b>0.4 mg Semaglutide</b> ) Sub-Q once weekly          |                |
| <input type="checkbox"/> DISP: 1 mL vial         | Inject 16 units ( <b>0.8 mg Semaglutide</b> ) Sub-Q once weekly         |                |
| <input type="checkbox"/> DISP: 1 mL vial         | Inject 24 units ( <b>1.2 mg Semaglutide</b> ) Sub-Q once weekly         |                |
| <input type="checkbox"/> DISP: 2 - 1 mL vials    | Inject 30 units ( <b>1.5 mg Semaglutide</b> ) Sub-Q once weekly         |                |
| <input type="checkbox"/> DISP: 2 - 1 mL vials    | Inject 24 units ( <b>1.2 mg Semaglutide</b> ) Sub-Q <b>twice</b> weekly | (2.4mg/week)   |
| <input type="checkbox"/> DISP: ____ 1 mL vial(s) | Inject subcutaneously weekly as directed by provider                    | (MAX: 4 VIALS) |
| <input type="checkbox"/> DISP: ____ 1 mL vial(s) | _____                                                                   |                |

☐ **Tirzepatide / Leucine / Pyridoxine 20 / 10 / 10 mg / mL**

- |                                                  |                                                                       |                |
|--------------------------------------------------|-----------------------------------------------------------------------|----------------|
| <input type="checkbox"/> DISP: 1 mL vial         | Inject 11 units ( <b>2.2 mg Tirzepatide</b> ) Sub-Q once weekly       |                |
| <input type="checkbox"/> DISP: 1 mL vial         | Inject 15 units ( <b>3 mg Tirzepatide</b> ) Sub-Q once weekly         |                |
| <input type="checkbox"/> DISP: 1 mL vial         | Inject 20 units ( <b>4 mg Tirzepatide</b> ) Sub-Q once weekly         |                |
| <input type="checkbox"/> DISP: 2 - 1 mL vials    | Inject 30 units ( <b>6 mg Tirzepatide</b> ) Sub-Q once weekly         |                |
| <input type="checkbox"/> DISP: 3 mL vial         | Inject 44 units ( <b>8.8 mg Tirzepatide</b> ) Sub-Q once weekly       |                |
| <input type="checkbox"/> DISP: 3 mL vial         | Inject 56 units ( <b>11.2 mg Tirzepatide</b> ) Sub-Q once weekly      |                |
| <input type="checkbox"/> DISP: 3 mL vial         | Inject 30 units ( <b>6 mg Tirzepatide</b> ) Sub-Q <b>twice</b> weekly | (12 mg/week)   |
| <input type="checkbox"/> DISP: ____ 1 mL vial(s) | Inject subcutaneously weekly as directed by provider                  | (MAX: 2 VIALS) |
| <input type="checkbox"/> DISP: ____ 1 mL vial(s) | _____                                                                 |                |
| <input type="checkbox"/> DISP: ____ 3 mL vial(s) | Inject subcutaneously weekly as directed by provider                  | (MAX: 2 VIALS) |
| <input type="checkbox"/> DISP: ____ 3 mL vial(s) | _____                                                                 |                |



Refills: \_\_\_\_\_

☐ **Ondansetron 4mg ODT DISP: 10 tablets** Dissolve 1 tablet under the tongue every 6-8 hours as needed for nausea Refills: \_\_\_\_\_